Prevalence of chronic comorbidities in people with multiple sclerosis: descriptive study based on administrative data in Tuscany (Central Italy)

Daiana Bezzini1 · Elisa Gualdani2 · Matilde Razzanelli2 · Mario Alberto Battaglia1,3 · Rosa Cortese4 · Paolo Francesconi2 · Monica Ulivelli4

Received: 28 April 2022 / Accepted: 11 August 2022 / Published online: 18 August 2022
© The Author(s) 2022

Abstract
Objective Chronic comorbidities are common in people with multiple sclerosis (PwMS), thus worsening their prognosis and quality of life, and increasing disease burden. The aim of the present study was to evaluate the prevalence of common comorbidities in PwMS in Tuscany (Central Italy) and to compare it with the general population.

Methods The prevalence of comorbidities, including diabetes, chronic obstructive pulmonary disease (COPD), hypertension, stroke, heart failure (HF), cardiac infarction and ischemic heart disease (IHD), was assessed in PwMS and in general population resident in Tuscany, aged > 20 years, using administrative data.

Results In total, we identified 8,274 PwMS. Among them, 34% had at least one comorbidity, with hypertension being the most common (28.5%). Comparing PwMS with the general population, PwMS had a higher frequency of hypertension and stroke when considering the whole group, and of diabetes, COPD, and IHD when considering sex and age subgroups. This increased risk was especially evident in the young and intermediate age groups, where multiple sclerosis may play an important role as risk factor for some comorbidities.

In PwMS, as well as in the general population, prevalence of chronic diseases was higher in males and increased with age.

Conclusions Comorbidities frequently coexist with multiple sclerosis and they may have an impact on this complex disease, from the health, clinical, and socioeconomic points of view. Therefore, a routine screening of chronic comorbidities should be a crucial step in clinical practice, as well as the promotion of healthy lifestyles to prevent the onset and to reduce their burden.

Keywords Multiple sclerosis · Chronic comorbidities · Prevalence · Administrative data · Sex-related differences · Age-related differences

Introduction
The identification of comorbidities (i.e., the presence of one or more chronic illness other than the disease of interest) has a key role in the management of people with multiple sclerosis (PwMS), as they can worsen the prognosis and the quality of life (QoL), influence disability status, healthcare utilization and hospitalization, treatment decisions and response, and increase the risk of death [1]. Comorbidities are common in PwMS due to the disease itself or related to the side effects of drugs [1], or to behavioral risk factors, such as smoking, physical inactivity, obesity, and unhealthy food intake [2]. Further, other chronic diseases may be more easily diagnosed in PwMS due to higher number of follow-up and a widespread use of the health service than the general population [3].

The prevalence of these conditions worldwide varies widely depending on the comorbidity considered, the specific patient population evaluated, and other factors such as demographic and genetic characteristics, socioeconomic condition, and geographic origin [3]. In 2015, an...
international review identified the most prevalent conditions, which were depression (23.7%), anxiety (21.9%), hypertension (18.6%), hyperlipidemia (10.9%), and chronic lung disease (10.0%) [1]. The authors concluded that there are only a few studies assessing the prevalence of concomitant diseases despite their importance for patients’ management and for the public health planning. Moreover, the majority of these studies are conducted in North America and Western Europe [1], while to date, there are only a few studies in Italy on the prevalence of comorbidities in PwMS. Tuscany is a high risk zone for multiple sclerosis (MS) [4], with a prevalence rate of 208.7 cases per 100,000 in 2017 [5] and an incidence rate of 6.6 cases in 2015 [6]. The evaluation of the concomitant presence of comorbidities and MS in this region of Central Italy has not been performed yet.

Among the currently available sources to capture comorbidities, such as clinical records, patients’ interviews, and administrative databases, the latest are the most cost- and time-saving, as they cover the whole population for a long period, and they are routinely collected, especially in countries with a publicly funded national healthcare system (NHS), such as Italy. However, being collected for the health system management and for the reimbursement by the NHS, and not for research purposes, these data need to be validated before their utilization [7].

In this study, we aimed to (i) assess the prevalence of comorbidities in PwMS in Tuscany, as at 1st of January 2019, using case-finding algorithms based on administrative data, and (ii) compare it with the general population. In particular, although many comorbidities are reported in PwMS, we selected some common chronic diseases, such as diabetes, hypertension, stroke, heart failure (HF), cardiac infarction, ischemic heart disease (IHD) and chronic obstructive pulmonary disease (COPD), because they are routinely monitored, through case-finding algorithms based on administrative data, by the Regional Health Agency of Tuscany to evaluate the public health.

### Study populations

To capture PwMS, it was applied a previous validated case-finding algorithm that used population-based, anonymized, administrative health data in which HOSP, EXE, DRUG, and LONG records were linked to inhabitant registry using the unique personal identification numbers that identify all Italian citizens [9].

The cohort of PwMS was composed by all inhabitants alive at the prevalence day who met at least one of the following criteria: (A) at least one HOSP record with MS diagnosis (ICD9CM 340), (B) one EXE record at 1/1/2019 for MS, (C) at least two DRUG records with different dates for at least one of the eight drugs that are specific for MS (see Table 1), and (D) MS diagnosis in LONG database.

### Methods

#### Data sources

Healthcare in Italy is universal, public, and regionally administrated. In observance of the privacy law, data were obtained from the Tuscan Health Administrative database that collects data for the health system management and for the reimbursement by the NHS, and covers the entire regional population (population aged more than 20 years at 1/1/2019: 2,917,181 with 1,379,469 males and 1,537,712 females). Further, the Regional Health Agency monitors administrative database for epidemiological surveillance of several chronic diseases and for control of quality of healthcare [8].

Main sources of administrative database are:

- Inhabitant registry with demographic information of all Tuscan citizens,
- Hospital discharge records (HOSP) reimbursed by the healthcare system, recorded with one main and up to 5 secondary diagnoses coded using the International Classification of Diseases, Ninth Revision (ICD9), and available from 1999,
- Exemption registry (EXE) collecting disease-specific exemptions from co-payment to the healthcare system, recorded with a ICD9 disease code,
- Drug dispensing registry (DRUG) that collects data of drugs with a medical prescription, dispensed directly by local health authorities to community-dwelling patients and/or by private or public pharmacies (available from 2004 and 2003, respectively). Drugs are coded using Anatomic Therapeutic Chemical classification system (ATC),
- Home and residential long-term care (LONG) coded with ICD9 disease code and available from 2010.

#### Table 1 List of drugs specific for MS used for our algorithm and their ATC code

| Pharmacophore                  | ATC code |
|-------------------------------|----------|
| Glatiramer acetate            | L03AX13  |
| Interferon beta 1A            | L03AB07  |
| Interferon beta 1B            | L03AB08  |
| Fingolimod                    | L04AA27  |
| Natalizumab                   | L04AA23  |
| Dimethyl fumarate             | N07XX09  |
| Peginterferon beta-1a         | L03AB13  |
| Teriflunomide                 | L04AA31  |

 Springer
Data were analyzed from the beginning of the recording of administrative data to the index date (1/1/2019), except for disease-specific payment exemptions regarding only the year before the prevalence date.

After identifying the MS cohort, patients aged under 20 years were excluded due to the minimum risk to present comorbidities in younger subjects and to compare these results with other published studies.

Similar algorithms, created and routinely used by the Tuscany Regional Health Agency to monitor other chronic diseases, were used to find in the general Tuscan population the cohorts of people affected (see Table 2). Then, patients’ groups were linked to identify our study cohort.

### Statistical analysis

Age and sex-standardized prevalence of comorbidities were calculated among PwMS and general population using the 2011 Tuscan population (last available population census) as standard. In order to establish the statistical significance of the differences in results obtained in PwMS versus general population, 95% confidence intervals (CI) were computed assuming a Poisson distribution.

### Results

As at 1st January 2019, 63% of the Tuscan population aged more than 20 did not have any of the analyzed chronic diseases, whereas 35% had diabetes and/or hypertension (cardiovascular risk group), 8% cerebro-cardiovascular diseases (including stroke, heart failure, cardiac infarction, and/or ischemic heart disease), and 6% had COPD. Around 10% of inhabitants had more than one comorbidity (Fig. 1).

Regarding MS, we identified 8,274 cases with a crude prevalence of 283.6 per 100,000 ab among population aged more than 20.

Among MS prevalent cases, we found 5,503 (66.5%) patients with no comorbidities, 2,354 cases (28.5%) with hypertension, 535 (6.5%) with diabetes, 396 with COPD

| Disease | Algorithm (inclusion criteria) | Validation |
|---------|--------------------------------|------------|
| Diabetes | (A) at least one HOSP record with diagnosis of diabetes (ICD9CM 250*) AND/OR (B) one EXE record at 1/1/2019 for diabetes, AND/OR (C) at least two DRUG record with different dates for drugs specific for diabetes (ATC A10), AND/OR (D) diabetes diagnosis LONG database | Positive predictive value (PPV) = 100% [36] |
| Stroke | (A) at least one HOSP record with primary diagnosis code 430, 431, 432, 436 AND/OR (B) ICD9CM 430, 431, 432, 434, 436 diagnosis in LONG database | No validation |
| Heart failure (HF) | (A) at least HOSP record with diagnosis of HF (428*, 39,891, 40,201, 40,211, 40,291, 40,401, 40,403, 40,411, 40,413, 40,491, 40,493) AND/OR (B) one EXE record at 1/1/2019 for ICD9CM 428, AND/OR (C) ICD9CM 428 diagnosis in LONG database | PPV = 55% [36] |
| Hypertension | (A) at least one HOSP record with one of these diagnosis codes 401*, 402*, 403*, 404*, 405*, 36, 211 AND/OR (B) one EXE record at 1/1/2019 for 401, 402, 403, 404, 405, AND/OR (C) at least two DRUG records with different dates for drugs specific for hypertension (ATC C09*, C02*, C07*, C08C), AND/OR (D) hypertension diagnosis (ICD9CM 401*, 402*, 403*, 404*, 405*) in LONG database | PPV = 100% [36] |
| COPD | (A) at least one HOSP record with diagnosis of ICD9CM 490*, 491*, 492*, 494*, 496*, AND/OR (B) DRUG records with different dates for drugs with a code ATC R03*, in particular: •Patients with 45 years of age or more, with more than 120 days between the first and the last prescription, at least 5 packs •Patients with 45 years of age or more, only one therapeutic class with an interval between the first and the last prescription ranging from 30 to 120 days, with a number of prescriptions ranging from 3 to 10 •Patients with 45 years of age or more, only one therapeutic class with an interval between the first and the last prescription ranging from 120 to 210 days, with a number of prescriptions ranging from 3 to 4 AND/OR (D) a diagnosis with one of the code 490*, 491*, 492*, 494*, 496* in LONG database | No validation |
| Cardiac infarction | (A) at least one HOSP record with diagnosis of ICD9CM 410* AND/OR (B) one EXE record at 1/1/2019 for ischemic heart disease (ICD9CM 414), AND/OR (C) at least two DRUG record with different dates for nitrates (ATC C01DA*), AND/OR (D) a diagnosis with one of the code 410–414 in LONG database | No validation |
| Ischemic heart disease (IHD) | (A) at least one HOSP record with diagnosis of ICD9CM 410*–414**, AND/OR (B) one EXE record at 1/1/2019 for ischemic heart disease (ICD9CM 414), AND/OR (C) at least two DRUG record with different dates for nitrates (ATC C01DA*), AND/OR (D) a diagnosis with one of the code 410–414 in LONG database | No validation |
(4.8%), 257 with IHD (3.1%), 201 (2.4%) with stroke, 122 (1.5%) with cardiac infarction, and 108 with HF (1.3%). Five hundred and sixty-seven PwMS (6.9%) had more than one comorbidity.

When analyzing age and sex-standardized prevalence rates of comorbidities among PwMS, the most common was hypertension with a prevalence of 246.5 per 1,000 followed by diabetes (61.8), COPD (58.1), and IHD (26.5), whereas stroke, cardiac infarction, and heart failure accounted for less than 20 cases per 1,000 MS patients (Table 3). When comparing these rates with the general population and considering all age groups together, we observed statistically higher prevalence rates in PwMS for stroke in both sexes, for diabetes and COPD only in females, and for hypertension only in males, whereas cardiac infarction was more common in general population for both sexes, and heart failure only in female (Table 3).

Considering subgroups by age, younger males and females with MS (20–44 years of age) had statistically significant higher rates of hypertension, stroke, and diabetes than the ones in the general population, whereas IHD was significantly higher only in males. The middle age MS group (45–59 years of age) had statistically significant higher rates of hypertension and COPD for both sexes and higher rates of stroke and IHD only in females. Among oldest group (> 60 years of age), PwMS had statistically significant higher rates of stroke for both sexes, and diabetes and COPD for males, whereas general population had statistically significant higher rates of heart failure for both sexes, and COPD and IHD for females only (Table 3).

**Discussion**

Studies on comorbidities are of great and increasing interest because these conditions are common in PwMS and, if not identified, they can have a direct impact on the disease, affecting clinical disability, and an indirect one due to their role as confounding factor during different disease phases. First, during the diagnostic phase, concomitant diseases could influence symptoms at onset leading to misdiagnosis. Secondly, prior to start specific treatments, comorbid conditions should be considered in MS, as they can limit or negatively affect the utilization of some disease modifying drugs (DMDs), especially in case of polypharmacy. Third, during the follow-up period, they can lead to a worsening of the clinical status, with an impact on MS prognosis and patients’ autonomy, empowerment, and quality of life.

In this study, the prevalence rates of comorbidities resemble those of published data, with hypertension being the most frequent comorbidity (around 30%) followed by diabetes (6%) [10, 11]. Specifically, resulting data from the Tuscan cohort showed a greater risk of developing comorbidities in PwMS, especially in the young and intermediate groups, suggesting an important role of MS as risk factor in these age classes.

As expected, an increasing trend is observed in both study populations with advancing age [12–14] and comorbidities were more frequent in males both in PwMS and in the general population [10]. This sex difference reflects the same trend already present in the Italian population, which could partly explain the lower survival age of males (80.8 years) than females (85.2 years) [15].

The increased risk of chronic diseases in MS may be related to the higher frequency of adverse health behaviors in PwMS, such as higher prevalence of smokers and a lower level of physical activity in comparison with the general population [16] and a low adherence to healthy diet [17]. A possible further explanation for this finding is called the “surveillance hypothesis”, because patients undergo to tighter screening programmes than healthy individuals which can reveal conditions otherwise hidden. Indeed, PwMS receive frequent screening and surveillance tests before and during treatment to monitor the potential side effects of these therapies. As they are closely monitored, it is possible to find comorbidities earlier in these patients than in the general population of the same age [18].

Alternatively, the “competing demands hypothesis” should be considered [18], which draws attention to the misattribution of symptoms by clinicians of a new comorbidity to MS causing an underestimation of comorbidities’ diagnosis.

Looking at the correlations between MS and its comorbidities, patients had a higher risk of hypertension in the first two age groups in both sexes compared to general population, although an increasing trend with age was observed in both populations. Considering the total population, 25% of PwMS was affected by hypertension, in line with a previous American study showing the same prevalence [11]. Hypertension brings to an increased risk of complications and it
### Table 3  
Standardized prevalence rates (per 1000 persons) of chronic diseases as at 1/1/2019, in PwMS and general population, according to sex and age group, and relative 95% confidence interval (CI 95%)

|       | Hypertension | Stroke | IHD | Diabetes | Heart failure | COPD | Cardiac infarction |
|-------|--------------|--------|-----|----------|--------------|------|--------------------|
|       | MS (CI 95%)  | GEN (CI 95%) | MS (CI 95%)  | GEN (CI 95%) | MS (CI 95%)  | GEN (CI 95%) | MS (CI 95%)  | GEN (CI 95%) |
| F:20–44 | 65.7 (50.5–80.7)  | 25.7 (21.3–28.1) | 5.7 (3.2–8.2) | 1.2 (0.8–1.7) | 3.9 (1.5–6.3) | 1.0 (0.4–1.5) | 24.5 (20.5–27.7) | 10.2 (7.3–13.7) |
| F:45–59 | 222.3 (207.6–237.4) | 135.8 (132.4–139.0) | 4.3 (6.4–11.4) | 11.3 (8.6–14.1) | 6.2 (4.3–8.4) | 3.5 (1.6–5.7) | 32.7 (28.3–36.4) | 31.4 (25.2–37.8) |
| F:60+  | 493.2 (478.4–508.6) | 523.6 (503.3–545.1) | 27.8 (24.7–31.6) | 51.2 (48.7–53.8) | 78.9 (65.4–91.4) | 124.4 (120.1–128.2) | 28.7 (26.4–30.5) | 36.4 (34.3–37.8) |
| Tot F  | 235.8 (221.8–248.4) | 218.7 (208.1–226.6) | 9.7 (7.3–11.6) | 19.0 (13.7–22.5) | 25.3 (21.6–29.2) | 58.6 (52.6–65.7) | 50.1 (49.8–51.4) | 8.6 (6.2–10.5) |
| M:20–44 | 58.2 (43.3–73.4) | 28.4 (24.3–32.2) | 1.5 (1.2–1.7) | 5.7 (3.4–8.2) | 2.0 (1.5–2.6) | 23.6 (19.3–27.5) | 8.7 (6.7–10.3) | 0.9 (0.5–1.4) |
| M:45–59 | 232.2 (136.6–142.8) | 139.5 (96.0–189.0) | 5.4 (3.0–7.9) | 22.3 (19.8–24.9) | 21.3 (18.5–24.6) | 45.4 (41.2–49.3) | 37.6 (32.4–42.7) | 4.9 (2.7–6.7) |
| M:60+  | 573.2 (558.3–588.2) | 535.6 (542.6–567.4) | 7.2 (7.1–12.1) | 34.8 (19.8–24.9) | 135.2 (15.5–26.4) | 181.1 (177.0–185.1) | 165.4 (154.6–176.2) | 51.4 (49.2–53.0) |
| Tot M  | 262.9 (245.3–276.5) | 232.2 (203.5–235.2) | 11.1 (9.9–12.2) | 44.5 (36.0–52.3) | 45.4 (40.1–51.6) | 72.4 (61.7–82.2) | 63.1 (59.7–67.3) | 15.5 (11.1–19.9) |
| TOT   | 246.5 (232.0–259.5) | 222.6 (219.7–226.5) | 16.8 (14.5–18.7) | 101.1 (82.6–120.0) | 26.5 (22.3–29.4) | 10.5 (7.3–11.7) | 61.8 (57.7–66.0) | 16.7 (9.2–11.2) |

Statistically significant differences are highlighted in bold.
could be linked, as other comorbidities, to autoimmunity and chronic inflammation of MS, in addition to other unhealthy lifestyles, such as a sedentary behavior, poor health, and socioeconomic status [19, 20].

Further, a higher prevalence of diabetes was observed in the younger age group of both sexes among PwMS than in the general population and, only in males, in the older age group. Unfortunately, with administrative data, it is not possible to differentiate the types of diabetes and consequently their distribution in different age and sex groups. Several studies showed that the autoimmune pathogenesis of MS might contribute to the predisposition to other comorbidities, including type 1 diabetes mellitus. Although type 1 diabetes accounts for only 10% of the total cases [21], this disease is of particular interest because it shares similar characteristics with MS, in terms of epidemiological distribution and aetiology. Indeed, they both showed a decreasing gradient of prevalence from north to south [22, 23], and they seem to have a common genetic risk [24]. In addition, another possible explanation is a similar viral origin [25, 26], in particular the association with the infection with Epstein-Barr virus [27, 28]. The correlation with MS and type 2 diabetes mellitus, on the other hand, could be explained not only with the unhealthy lifestyle in PwMS but also with the use of corticosteroid therapy [26, 29].

In our study, we found that the prevalence of stroke is higher in PwMS than in the general population irrespective of sex and age, in line with the literature [30, 31]. The risk of developing cerebrovascular disease has been evaluated in PwMS and, although there are discordant findings [32], it seems that there is an increased risk of stroke especially in the years immediately following the diagnosis of MS [33]. Causes of different nature have been suggested: surveillance hypothesis, misdiagnosis, utilization of high doses of corticosteroids for relapses [30], the higher presence of antiphospholipid antibodies in PwMS than in general population [33], and dysregulated inflammatory processes, characterizing MS, increasing risk of arterial atherosclerosis, and consequently of stroke [34].

When considering CV diseases, they must be taken into account as confounding factors themselves and as contraindication or side effect to the use of some DMDs [35]. In the present study, IHD prevalence was higher in females with MS in the middle age group and in males with MS in the younger age group, whereas is higher in females in the general population in the older age group. However, the prevalence was generally higher in males, both in MS and in the general population. Literature data regarding the association of IHD and MS are conflicting [35]: a recent review finds no increased risk in MS [36], whereas another study reveals an increased risk of IHD in males with MS under 60 years of age, confirming our results [35]. IHD in PwMS seems to be linked to an increased risk of complications of the clinical picture and a reduction in survival [35, 37]. Possible reasons of this association may be a poor physical activity in PwMS and/or the common presence of hypertension, hyperlipidemia, and diabetes as non-specific risk factors for cerebro-cardiovascular disease [35].

Regarding cardiac infarction only, data showed a higher prevalence in the total general population vs MS one. Literature data on myocardial infarction, on the other hand, are discordant, also in view of characteristics of the different populations under study. Moreover, several studies suggested that, in addition to the common risk factors, the inflammatory state (also common to other immune-mediated diseases) may independently increase the possibility of developing these diseases [38]. Concerning the risk of heart failure, this study did not show any differences between PwMS and general population in the younger and intermediate age groups for both sexes, while in the over 60 age group, there is an increased prevalence in the general population compared to MS one. These results are not confirmed in previous works: indeed, a study conducting on a large Danish MS cohort reveals a slightly higher risk of acute myocardial infarction, stroke, and heart failure within the first year after MS diagnosis in comparison with the general population. This increased risk persisted, during long-term follow-up, for stroke and heart failure [39].

Chronic pulmonary diseases, and COPD in particular, occur with high frequency as comorbidity in young PwMS [14]. In this study, we found an increased risk in people with MS in the young and intermediate age groups (statistically significant only in the second group). In the older age group, however, the same correlation was observed only in males, while in females, the general population was at greater risk than those with MS. The cause of this comorbidity probably lies both in the disability itself, which leads to a sedentary lifestyle. Disability is therefore the primum movens causing a series of consequences (principally an unhealthy lifestyle and a reduced physical exercise), which in PwMS could lead, in the long term, to a worsening of the clinical condition. In addition, the presence of chronic diseases of pulmonary origin may complicate or be a complication of some DMDs [14].

A strength of our study is the use of administrative data, which represent a cost- and time-saving tool for the identification of chronic disorders and their relationship with MS, essential for a targeted public health planning. This source of data is also a limitation of our study due to the nature of administrative data which are not collected for scientific purposes, and they do not include clinical information on patients which might allow further comparisons and consideration.
Conclusions

In conclusion, our findings confirm that PwMS have an increased prevalence of comorbidities, which may impact their already complex clinical picture. The identification and management of other chronic diseases is particularly noteworthy, as it may improve the clinical management of PwMS in all disease stages.

Fortunately, many of these comorbidities are related to modifiable risk factors. Therefore, it should be of primary importance in clinical practice to routinely screen patients for chronic diseases and to educate PwMS to healthy lifestyles. A multidisciplinary team including the general practitioner is needed to assess and assist patients in order to improve their quality of life, reduce disability, and increase patients’ survival.

Funding Open access funding provided by Università degli Studi di Siena within the CRUI-CARE Agreement.

Data availability Data presented here are available upon request to the corresponding author.

Declarations

Competing interests The authors declare no competing interests.

Ethics approval The manuscript does not contain clinical studies or patient data.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Marrie RA, Cohen J, Stuve O et al (2015) A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult Scler J 21:263–281. https://doi.org/10.1177/1352458514564491
2. Marrie R, Horwitz R, Cutter G et al (2009) High frequency of adverse health behaviors in multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 15:105–113. https://doi.org/10.1177/1352458508096680
3. Marrie RA, Horwitz RI (2010) Emerging effects of comorbidities on multiple sclerosis. Lancet Neurol 9:820–828. https://doi.org/10.1016/S1474-4422(10)70135-6
4. Battaglia MA, Bezzi D (2017) Estimated prevalence of multiple sclerosis in Italy in 2015. Neurul Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 38:473–479. https://doi.org/10.1007/s10072-016-2801-9
5. Bezzi D, Ulivelli M, Gualdani E et al (2020) Increasing prevalence of multiple sclerosis in Tuscany, Italy. Neurul Sci 41:397–402. https://doi.org/10.1007/s10072-019-04090-0
6. Bezzi D, Policardo L, Profili F et al (2018) Multiple sclerosis incidence in Tuscany from administrative data. Neurul Sci 39:1881–1885. https://doi.org/10.1007/s10072-018-3513-0
7. Marrie RA, Yu BN, Leung S et al (2012) Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Mult Scler J 18:1310–1319. https://doi.org/10.1177/1352458512437814
8. baldocchi caterina La banca dati delle malattie croniche - Aggiornamento 2018. In: ARS Agenzia Reg. Sanità Toscana. https://www.ars.toscana.it/2-articoli/3949-la-banca-dati-delle-malattie-croniche-aggiornamento-2018.html. Accessed 30 Jan 2022
9. Bezzi D, Policardo L, Meucci G et al (2016) Prevalence of multiple sclerosis in Tuscany (Central Italy): a study based on validated administrative data. Neuroepidemiol 46:37–42. https://doi.org/10.1159/000441567
10. Marrie R, Horwitz R, Cutter G et al (2008) Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler Houndmills Basingstoke Engl 14:1091–1098. https://doi.org/10.1177/13524580992263
11. Edwards NC, Munsell M, Menzin J, Phillips AL (2018) Comorbidity in US patients with multiple sclerosis. Patient Relat Outcome Meas 9:97–102. https://doi.org/10.2147/PROM.S148387
12. Capkun G, Dahlke F, Lahoz R et al (2015) Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: an observational study using the US Department of Defense administrative claims database. Mult Scler Relat Disord 4:546–554. https://doi.org/10.1016/j.msard.2015.08.005
13. Goodin DS, Corwin M, Kaufman D et al (2014) Causes of death among commercially insured multiple sclerosis patients in the United States, PLoS ONE 9:e105207. https://doi.org/10.1371/journal.pone.0105207
14. Marrie RA, Patten S, Tremlett H et al (2016) Chronic lung disease and multiple sclerosis: incidence, prevalence, and temporal trends. Mult Scler Relat Disord 8:86–92. https://doi.org/10.1016/j.msard.2016.05.009
15. (2021) Rapporto Bes 2019: il benessere equo e sostenibile in Italia. https://www.istat.it/it/archivio/236714. Accessed 30 Jan 2022
16. Motl RW, McAuley E, Snook EM (2005) Physical activity and multiple sclerosis: a meta-analysis. Mult Scler Houndmills Basingstoke Engl 11:459–463. https://doi.org/10.1177/1352458505ms11880a
17. Balto JM, Ensari I, Hubbard EA et al (2016) Individual and co-occurring SNAP risk factors. Int J MS Care 18:298–304. https://doi.org/10.10724/1537-2073.2016-040
18. Marrie RA (2019) Comorbidity in multiple sclerosis past, present and future. Clin Investig Med Med Clin Exp 42:E5–E12. https://doi.org/10.25011/cim.v42i1.32383
19. Hubbard EA, Motl RW, Fernhall B (2018) Sedentary behavior and blood pressure in patients with multiple sclerosis. Int J MS Care 20:1–8. https://doi.org/10.10724/1537-2073.2016-021
20. Sorensen A, Conway DS, Briggs FBS (2021) Characterizing relapsing remitting multiple sclerosis patients burdened with...
hypertension, hyperlipidemia, and asthma. Mult Scler Relat Disord 53:103040. https://doi.org/10.1016/j.msard.2021.103040
21. Ministero della Salute Diabete mellito tipo 2. https://www.salute.gov.it/portale/nutrizione/dettaglioContenutiNutrizione.jsp?lingua=italiano&id=5511&area=nutrizione&menu=croniche. Accessed 29 Jan 2022
22. Koch-Henriksen N, Sorensen PS (2011) Why does the north–south gradient of incidence of multiple sclerosis seem to have disappeared on the Northern hemisphere? J Neurol Sci 311:58–63. https://doi.org/10.1016/j.jns.2011.09.003
23. Liese AD, Lawson A, Song H-R et al (2010) Evaluating geographic variation in type 1 and type 2 diabetes mellitus incidence in youth in four US regions. Health Place 16:547–556. https://doi.org/10.1016/j.healthplace.2009.12.015
24. Marrosu MG, Cocco E, Lai M et al (2002) Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study. The Lancet 359:1461–1465. https://doi.org/10.1016/S0140-6736(02)08431-3
25. Jankosky C, Deussing E, Gibson RL, Havercos HW (2012) Viruses and vitamin D in the etiology of type 1 diabetes mellitus and multiple sclerosis. Virus Res 163:424–430. https://doi.org/10.1016/j.virusres.2011.11.010
26. Hussein WI, Reddy SS (2006) Prevalence of diabetes in patients with multiple sclerosis. Diabetes Care 29:1984–1985. https://doi.org/10.2337/dc06-0811
27. Harley JB, Chen X, Pujato M et al (2018) Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat Genet 50:699–707. https://doi.org/10.1038/s41588-018-0102-3
28. Bjornevik K, Cortese M, Healy BC et al (2022) Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Sci 375:296–301. https://doi.org/10.1126/science.abj8222
29. Marck CH, Neate SL, Taylor KL et al (2016) Prevalence of comorbidities, overweight and obesity in an international sample of people with multiple sclerosis and associations with modifiable lifestyle factors. PLoS ONE 11:e0148573. https://doi.org/10.1371/journal.pone.0148573
30. Hong Y, Tang HR, Ma M et al (2019) Multiple sclerosis and stroke: a systematic review and meta-analysis. BMC Neurol 19:139. https://doi.org/10.1186/s12883-019-1366-7
31. Cárdenas-Robledo S, Otero-Romero S, Passarell-Bacardit MA et al (2021) Multiple sclerosis is associated with higher comorbidity and health care resource use: a population-based, case-control study in a western Mediterranean region. Eur J Neurol 28:4124–4134. https://doi.org/10.1111/ene.15030
32. Geraldes R, Esiri MM, Perera R et al (2020) Vascular disease and multiple sclerosis: a post-mortem study exploring their relationships. Brain J Neurol 143:2998–3012. https://doi.org/10.1093/brain/awaa255
33. LeVine SM (2016) Is there an increased risk for ischemic stroke in patients with multiple sclerosis, and if so, should preventive treatment be considered? Front Neurol 7. https://doi.org/10.3389/fneur.2016.00128
34. Tseng C-H, Huang W-S, Lin C-L, Chang Y-J (2015) Increased risk of ischaemic stroke among patients with multiple sclerosis. Eur J Neurol 22:500–506. https://doi.org/10.1111/ene.12598
35. Marrie RA, Yu BN, Leung S et al (2013) Prevalence and incidence of ischemic heart disease in multiple sclerosis: a population-based validation study. Mult Scler Relat Disord 2:355–361. https://doi.org/10.1016/j.msard.2013.03.001
36. Rapp D,Michels S, Schöpe J et al (2021) Associations between multiple sclerosis and incidence of heart diseases: systematic review and meta-analysis of observational studies. Mult Scler Relat Disord 56:103279. https://doi.org/10.1016/j.msard.2021.103279
37. Marrie RA, Yu BN, Leung S et al (2013) The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. Neuroepidemiol 40:85–92. https://doi.org/10.1159/000343188
38. Marrie RA, Garland A, Schaffer SA et al (2019) Traditional risk factors may not explain increased incidence of myocardial infarction in MS. Neurool 92:e1624–e1633. https://doi.org/10.1212/WNL.0000000000007251
39. Christiansen CF, Christensen S, Farkas DK et al (2010) Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study. Neuroepidemiol 35:267–274. https://doi.org/10.1159/000320245

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.